The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host

1.

Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–70.PubMed

2.

Liotta, L. A., & Kohn, E. C. (2001). The microenvironment of the tumour–host interface. Nature, 411, 375–379.PubMed

3.

Murphy-Ullrich, J. E. (2001). The de-adhesion activity of matricellular proteins: Is intermediate cell adhesion an adaptive state? Journal of Clinical Investigation, 107(7), 785–790.PubMed

4.

Bornstein, P. (2002). Cell–matrix interactions: The view from the outside. Methods in Cell Biology, 69, 7–11.PubMed

5.

Sage, E. H. (2001). Regulation of interactions between cells and extracellular matrix: A command performance on several stages. Journal of Clinical Investigation, 107(7), 781–783.PubMed

6.

Rosenblatt, S., Bassuk, J. A., Alpers, C. E., Sage, E. H., Timpl, R., & Preissner, K. T. (1997). Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: Characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Biochemical Journal, 324, 311–319.PubMed

7.

Xie, R. L., & Long, G. L. (1995). Role of N-linked glycosylation in human osteonectin. Effect of carbohydrate removal by N-glycanase and site-directed mutagenesis on structure and binding of type V collagen. Journal of Biological Chemistry, 270(39), 23212–23217.PubMed

8.

Maurer, P., Hohenadl, C., Hohenester, E., Gohring, W., Timpl, R., & Engel, J. (1995). The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domains that binds calcium and collagen IV. Journal of Molecular Biology, 253(2), 347–357.PubMed

9.

Raines, E. W., Lane, T. F., Iruela-Arispe, M. L., Ross, R., & Sage, E. H. (1992). The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and BB and inhibits the binding of PDGF to its receptors. Proceedings of the National Academy of Sciences of the United States of America, 89, 1281–1285.PubMed

10.

Hasselaar, P., & Sage, E. H. (1992). SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. Journal of Cellular Biochemistry, 49, 272–283.PubMed

11.

Tremble, P. M., Lane, T. F., Sage, E. H., & Werb, Z. (1993). SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. Journal of Cell Biology, 121(6), 1433–1444.PubMed

12.

Ledda, M. F., Adris, S., Bravo, A. I., Kairiyama, C., Bover, L., Chernajovsky, Y., et al. (1997). Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nature Medicine, 3(2), 171–175.PubMed

13.

Lane, T. F., Iruela-Arispe, M. L., & Sage, E. H. (1992). Regulation of gene expression by SPARC during angiogenesis in vitro, changes in fibronectin, thrombospondin-1 and plasminogen activator inhibitor-1. Journal of Biological Chemistry, 267(23), 16736–16745.PubMed

14.

Gilles, C., Bassuk, J. A., Pulyaeva, H., Sage, E. H., Foidart, J.-M., & Thompson, E. W. (1998). SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Research, 58(23), 5529–5536.PubMed

15.

Murphy-Ullrich, J. E., Lane, T. F., Pallero, M. A., & Sage, E. H. (1995). SPARC mediates focal adhesion disassembly in endothelial cells through a follistatin-like region and the Ca2+ binding EF-hand. Journal of Cellular Biochemistry, 57, 341–350.PubMed

16.

Brekken, R. A., & Sage, E. H. (2000). SPARC, a matricellular protein: At the crossroads of cell–matrix. Matrix Biology, 19(7), 569–580.PubMed

17.

Bradshaw, A. D., Francki, A., Motamed, K., Howe, C., & Sage, E. H. (1999). Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Molecular Biology of the Cell, 10(5), 1569–1579.PubMed

18.

Ledda, M. F., Bravo, A. I., Adris, S., Bover, L., Mordoh, J., & Podhajcer, O. L. (1997). The expression on the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. Journal of Investigative Dermatology, 108(2), 210–214.PubMed

19.

Rumpler, G., Becker, B., Hafner, C., McClelland, M., Stolz, W., Landthaler, M., et al. (2003). Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Experimental Dermatology, 12(6), 761–771.PubMed

20.

Massi, D., Franchi, A., Borgognoni, L., Reali, U. M., & Santucci, M. (1999). Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Human Pathology, 30(3), 339–344.PubMed

21.

Ikuta, Y., Nakatsura, T., Kageshita, T., Fukushima, S., Ito, S., Wakamatsu, K., et al. (2005). Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clinical Cancer Research, 11(22), 8079–8088.PubMed

22.

Sosa, M. S., Girotti, M. R., Salvatierra, E., Prada, F., de Olmo, J. A., Gallango, S. J., et al. (2007). Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics, 7(22), 4123–4134.PubMed

23.

Smit, D. J., Gardiner, B. B., & Sturm, R. A. (2007). Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. International Journal of Cancer, 121(12), 2653–2660.

24.

Porter, P. L., Sage, E. H., Lane, T. F., Funk, S. E., & Gown, A. M. (1995). Distribution of SPARC in normal and neoplastic human tissue. Journal of Histochemistry and Cytochemistry, 43(8), 791–800.PubMed

25.

Bellahcene, A., & Castronovo, V. (1995). Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. American Journal of Pathology, 146(1), 95–100.PubMed

26.

Podhajcer, O. L., Wolf, C., Lefebvre, O., Segain, J. P., Rouyer, N., Stoll, I., et al. (1996). Comparative expression of the SPARC and stromelysin-3 genes in mammary tumors. The Breast, 5, 13–20.

27.

Jones, C., Mackay, A., Grigoriadis, A., Cossu, A., Reis-Filho, J. S., Fulford, L., et al. (2004). Expression profiling of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer. Cancer Research, 64(9), 3037–3045.PubMed

28.

Lien, H. C., Hsiao, Y. H., Lin, Y. S., Yao, Y. T., Juan, H. F., Kuo, W. H., et al. (2007). Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: Identification of genes potentially related to epithelial–mesenchymal transition. Oncogene, 26(57), 7859–7871.PubMed

29.

Barth, P. J., Moll, R., & Ramaswamy, A. (2005). Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Archiv, 446(5), 532–536.PubMed

30.

Parker, B. S., Argani, P., Cook, B. P., Liangfeng, H., Chartrand, S. D., Zhang, M., et al. (2004). Alterations in vascular gene expression in invasive breast carcinoma. Cancer Research, 64(21), 7857–7866.PubMed

31.

Iacobuzio-Donahue, C. A., Argani, P., Hempen, P. M., Jones, J., & Kern, S. E. (2002). The desmoplastic response to infiltrating breast carcinoma: Gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Research, 62(18), 5351–5357.PubMed

32.

Graham, J. D., Balleine, R. L., Milliken, J. S., Bilous, A. M., & Clarke, C. L. (1997). Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content. European Journal of Cancer, 33(10), 1654–1660.PubMed

33.

Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., et al. (2005). Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clinical Cancer Research, 11(14), 5175–5180.PubMed

34.

Watkins, G., Douglas-Jones, A., Bryce, R., Mansel, R. E., & Jiang, W. G. (2005). Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins, Leukotrienes and Essential Fatty Acids, 72(4), 267–272.

35.

Rempel, S. A., Golembieski, W. A., Ge, S., Lemke, N., Elisevich, K., Mikkelsen, T., et al. (1998). SPARC: A signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. Journal of Neuropathology and Experimental Neurology, 57(12), 1112–1121.PubMed

36.

Golembieski, W. A., Ge, S., Nelson, K., Mikkelsen, T., & Rempel, S. A. (1999). Increased SPARC expression promotes U87 glioblastoma invasion in vitro. International Journal of Developmental Neuroscience, 17(5–6), 463–472.PubMed

37.

Rich, J. N., Shi, Q., Hjelmeland, M., Cummings, T. J., Kuan, C. T., Bigner, D. D., et al. (2003). Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. Journal of Biological Chemistry, 278(18), 15951–15957.PubMed

38.

Schultz, C., Lemke, N., Ge, S., Golembieski, W. A., & Rempel, S. A. (2002). Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Research, 62, 6270–6277.PubMed

39.

Vajkoczy, P., Manger, M. D., Goldbrunner, R., Ge, S., Fong, T. A., Vollmar, B., et al. (2000). Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. International Journal of Cancer, 87(2), 261–268.

40.

Shi, Q., Bao, S., Maxwell, J. A., Reese, E. D., Friedman, H. S., Bigner, D. D., et al. (2004). Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. Journal of Biological Chemistry, 279(50), 52200–52209.PubMed

41.

McClung, H. M., Thomas, S. L., Osenkowski, P., Toth, M., Menon, P., Raz, A., et al. (2007). SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neuroscience Letters, 419(2), 172–177.PubMed

42.

Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436(7050), 518–524.PubMed

43.

Campo-McKnight, D. A., Sosnoski, D. M., Koblinski, J. E., & Gay, C. V. (2006). Roles of osteonectin in the migration of breast cancer cells into bone. Journal of Cellular Biochemistry, 97(2), 288–302.PubMed

44.

Jacob, K., Webber, M., Benayahu, D., & Kleinman, H. K. (1999). Osteonectin promotes prostate cancer cell migration and invasion: Possible mechanism for metastasis to bone. Cancer Research, 59(17), 4453–4457.PubMed

45.

De, S., Chen, J., Narizhneva, N. V., Heston, W., Brainard, J., Sage, E. H., et al. (2003). molecular pathway for cancer metastasis to bone. Journal of Biological Chemistry, 278(40), 39044–39050.PubMed

46.

Chen, N., Ye, X. C., Chu, K., Navone, N. M., Sage, E. H., Yu-Lee, L. Y., et al. (2007). A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Research, 67(14), 6544–6548.PubMed

47.

Koblinski, J. E., Kaplan-Singer, B. R., VanOsdol, S. J., Wu, M., Engbring, J. A., Wang, S., et al. (2005). Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Research, 65(16), 7370–7377.PubMed

48.

Finocchiaro, G., Mancuso, F. M., Cittaro, D., & Muller, H. (2007). Graph-based identification of cancer signaling pathways from published gene expression signatures using PubLiME. Nucleic Acids Research, 35(7), 2343–2355.PubMed

49.

Chlenski, A., Liu, S., Crawford, S. E., Volpert, O. V., DeVries, G. H., Evangelista, A., et al. (2002). SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Research, 62(24), 7357–7363.PubMed

50.

Chlenski, A., Liu, S., Baker, L. J., Yang, Q., Tian, Y., Salwen, H. R., et al. (2004). Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. Cancer Research, 64(20), 7420–7425.PubMed

51.

Said, N., Socha, M. J., Olearczyk, J. J., Elmarakby, A. A., Imig, J. D., & Motamed, K. (2007). Normalization of the ovarian cancer microenvironment by SPARC. Molecular Cancer Research, 5(10), 1015–1030.PubMed

52.

Said, N. A., Najwer, I., Socha, M. J., Fulton, D. J., Mok, S. C., & Motamed, K. (2007). SPARC inhibits LPA-mediated mesothelial–ovarian cancer cell crosstalk. Neoplasia, 9(1), 23–35.PubMed

53.

Yiu, G. K., Chan, W. Y., Ng, S. W., Chan, P. S., Cheung, K. K., Berkowitz, R. S., et al. (2001). SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. American Journal of Pathology, 159(2), 609–622.PubMed

54.

Mok, S. C., Chan, W. Y., Wong, K. K., Muto, M. G., & Berkowitz, R. S. (1996). SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene, 12, 1895–1901.PubMed

55.

Said, N., & Motamed, K. (2005). Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. American Journal of Pathology, 167(6), 1739–1752.PubMed

56.

Brown, T. J., Shaw, P. A., Karp, X., Huynh, M. H., Begley, H., & Ringuette, M. J. (1999). Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecologic Oncology, 75(1), 25–33.PubMed

57.

Tai, I. T., Dai, M., Owen, D. A., & Chen, L. B. (2005). Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. Journal of Clinical Investigation, 115(6), 1492–1502.PubMed

58.

Taghizadeh, F., Tang, M. J., & Tai, I. T. (2007). Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Molecular Cancer Therapeutics, 6(1), 309–317.PubMed

59.

Tang, M. J., & Tai, I. T. (2007). A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. Journal of Biological Chemistry, 282(47), 34457–34467.PubMed

60.

Yang, E., Kang, H. J., Koh, K. H., Rhee, H., Kim, N. K., & Kim, H. (2007). Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. International Journal of Cancer, 121(3), 567–575.

61.

Wiese, A. H., Auer, J., Lassmann, S., Nahrig, J., Rosenberg, R., Hofler, H., et al. (2007). Identification of gene signatures for invasive colorectal tumor cells. Cancer Detection and Prevention, 31(4), 282–295.PubMed

62.

Nguyen, Q. D., De Wever, O., Bruyneel, E., Hendrix, A., Xie, W. Z., Lombet, A., et al. (2005). Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho–Rho kinase axis and tumor microenvironment. Oncogene, 24(56), 8240–8251.PubMed

63.

Porte, H., Chastre, E., Prevot, S., Nordlinger, B., Empereur, S., Basset, P., et al. (1995). Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. International Journal of Cancer, 64, 70–75.

64.

Guweidhi, A., Kleeff, J., Adwan, H., Giese, N. A., Wente, M. N., Giese, T., et al. (2005). Osteonectin influences growth and invasion of pancreatic cancer cells. Annals of Surgery, 242(2), 224–234.PubMed

65.

Infante, J. R., Matsubayashi, H., Sato, N., Tonascia, J., Klein, A. P., Riall, T. A., et al. (2007). Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. Journal of Clinical Oncology, 25(3), 319–325.PubMed

66.

Koukourakis, M. I., Giatromanolaki, A., Brekken, R. A., Sivridis, E., Gatter, K. C., Harris, A. L., et al. (2003). Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Research, 63(17), 5376–5380.PubMed

67.

Sato, N., Fukushima, N., Maehara, N., Matsubayashi, H., Koopmann, J., Su, G. H., et al. (2003). SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor–stromal interactions. Oncogene, 22(32), 5021–5030.PubMed

68.

López-Haber, C., Gottifredi, V., Llera, A. S., Salvatierra, E., Prada, F., Alonso, L., et al. (2008). SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated. International Journal of Cancer, 122(7), 1465–1475.

69.

Prada, F., Benedetti, L. G., Bravo, A. I., Alvarez, M. J., Carbone, C., & Podhajcer, O. L. (2007). SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. Journal of Investigative Dermatology, 127(11), 2618–2628.PubMed

70.

Brekken, R. A., Puolakkainen, P., Graves, D. C., Workman, G., Lubkin, S. R., & Sage, E. H. (2003). Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. Journal of Clinical Investigation, 111(4), 487–495.PubMed

71.

Sangaletti, S., Stoppacciaro, A., Guiducci, C., Torrisi, M. R., & Colombo, M. P. (2003). Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. Journal of Experimental Medicine, 198(10), 1475–1485.PubMed

72.

Framson, P. E., & Sage, E. H. (2004). SPARC and tumor growth: Where the seed meets the soil? Journal of Cellular Biochemistry, 92(4), 679–690.PubMed

73.

Gooden, M. D., Vernon, R. B., Bassuk, J. A., & Sage, E. H. (1999). Cell cycle-dependent nuclear location of the matricellular protein SPARC: Association with the nuclear matrix. Journal of Cellular Biochemistry, 74(2), 152–167.PubMed

74.

Sodek, J., Zhu, B., Huynh, M. H., Brown, T. J., & Ringuette, M. (2002). Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connective Tissue Research, 43(2–3), 308–319.PubMed

75.

Yan, Q., Weaver, M., Perdue, N., & Sage, E. H. (2005). Matricellular protein SPARC is translocated to the nuclei of immortalized murine lens epithelial cells. Journal of Cellular Physiology, 203(1), 286–294.PubMed

76.

Sage, E. H., Johnson, C., & Bornstein, P. (1984). Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. Journal of Biological Chemistry, 259, 3993–4007.PubMed

77.

Funk, S. E., & Sage, E. H. (1993). Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. Journal of Cellular Physiology, 154, 53–63.PubMed

78.

Funk, S. E., & Sage, E. H. (1991). The Ca²⁺-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proceedings of the National Academy of Sciences of the United States of America, 88, 2648–2652.PubMed

79.

Kupprion, C., Motamed, K., & Sage, E. H. (1998). SPARC (BM-40, Osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. Journal of Biological Chemistry, 273(45), 29635–29640.PubMed

80.

Lau, C. P., Poon, R. T., Cheung, S. T., Yu, W. C., & Fan, S. T. (2006). SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. Journal of Pathology, 210(4), 459–468.PubMed

81.

Charest, A., Pepin, A., Shetty, R., Cote, C., Voisine, P., Dagenais, F., et al. (2006). Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart, 92(12), 1844–1849.PubMed

82.

Iruela Arispe, M. L., Lane, T. F., Redmond, D., Reilly, M., Bolender, R. P., Kavanagh, T. J., et al. (1995). Expression of SPARC during development of the chicken chorioallantoic membrane: Evidence for regulated proteolysis in vivo. Molecular Biology of the Cell, 6(3), 327–343.PubMed

83.

Lane, T. F., Iruela-Arispe, M. L., Johnson, R. S., & Sage, E. H. (1994). SPARC is a source of copper-binding peptides that stimulate angiogenesis. Journal of Cell Biology, 125, 929–943.PubMed

84.

Sage, E. H., Reed, M., Funk, S. E., Truong, T., Steadele, M., Puolakkainen, P., et al. (2003). Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. Journal of Biological Chemistry, 278(39), 37849–37857.PubMed

85.

Sasaki, T., Miosge, N., & Timpl, R. (1999). Immunochemical and tissue analysis of protease generated neoepitopes of BM-40 (osteonectin, SPARC) which are correlated to a higher affinity binding to collagens. Matrix Biology, 18(5), 499–508.PubMed

86.

Kato, Y., Lewalle, J. M., Baba, Y., Tsukuda, M., Sakai, N., Baba, M., et al. (2001). Induction of SPARC by VEGF in human vascular endothelial cells. Biochemical and Biophysical Research Communications, 287(2), 422–426.PubMed

87.

Nozaki, M., Sakurai, E., Raisler, B. J., Baffi, J. Z., Witta, J., Ogura, Y., et al. (2006). Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. Journal of Clinical Investigation, 116(2), 422–429.PubMed

88.

Ferrari, G., Pintucci, G., Seghezzi, G., Hyman, K., Galloway, A. C., & Mignatti, P. (2006). VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 103(46), 17260–17265.PubMed

89.

Choi, M. E., & Ballermann, B. J. (1995). Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors. Journal of Biological Chemistry, 270(36), 21144–21150.PubMed

90.

Thiery, J. P. (2002). Epithelial–mesenchymal transitions in tumour progression. Nature Reviews. Cancer, 2(6), 442–454.PubMed

91.

Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., et al. (2000). The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology, 2(2), 76–83.PubMed

92.

De Craene, B., van Roy, F., & Berx, G. (2005). Unraveling signalling cascades for the Snail family of transcription factors. Cellular Signalling, 17(5), 535–547.PubMed

93.

Moreno-Bueno, G., Cubillo, E., Sarrio, D., Peinado, H., Rodriguez-Pinilla, S. M., Villa, S., et al. (2006). Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial–mesenchymal transition. Cancer Research, 66(19), 9543–9556.PubMed

94.

Robert, G., Gaggioli, C., Bailet, O., Chavey, C., Abbe, P., Aberdam, E., et al. (2006). SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Research, 66(15), 7516–7523.PubMed

95.

Alonso, S. R., Tracey, L., Ortiz, P., Perez-Gomez, B., Palacios, J., Pollan, M., et al. (2007). A high-throughput study in melanoma identifies epithelial–mesenchymal transition as a major determinant of metastasis. Cancer Research, 67(7), 3450–3460.PubMed

96.

Bierie, B., & Moses, H. L. (2006). Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nature Reviews. Cancer, 6(7), 506–520.PubMed

97.

Ford, R., Wang, G., Jannati, P., Adler, D., Racanelli, P., Higgins, P. J., et al. (1993). Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: Regulation via a TGF-beta-dependent pathway. Experimental Cell Research, 206(2), 261–275.PubMed

98.

Bassuk, J. A., Pichler, R., Rothmier, J. D., Pippen, J., Gordon, K., Meek, R. L., et al. (2000). Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis. Kidney International, 57(1), 117–128.PubMed

99.

Francki, A., Bradshaw, A. D., Bassuk, J. A., Howe, C. C., Couser, W. G., & Sage, E. H. (1999). SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. Journal of Biological Chemistry, 274(45), 32145–32152.PubMed

100.

Reed, M. J., Vernon, R. B., Abrass, I. B., & Sage, E. H. (1994). TGF-b 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. Journal of Cellular Physiology, 158(1), 169–179.PubMed

101.

Shiba, H., Uchida, Y., Kamihagi, K., Sakata, M., Fujita, T., Nakamura, S., et al. (2001). Transforming growth factor-beta1 and basic fibroblast growth factor modulate osteocalcin and osteonectin/SPARC syntheses in vitamin-D-activated pulp cells. Journal of Dental Research, 80(7), 1653–1659.PubMedCrossRef

102.

Wrana, J. L., Overall, C. M., & Sodek, J. (1991). Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. Comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. European Journal of Biochemistry, 197, 519–528.PubMed

103.

Pavasant, P., Yongchaitrakul, T., Pattamapun, K., & Arksornnukit, M. (2003). The synergistic effect of TGF-beta and 1,25-dihydroxyvitamin D3 on SPARC synthesis and alkaline phosphatase activity in human pulp fibroblasts. Archives of Oral Biology, 48(10), 717–722.PubMed

104.

Francki, A., McClure, T. D., Brekken, R. A., Motamed, K., Murri, C., Wang, T., et al. (2004). SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. Journal of Cellular Biochemistry, 91(5), 915–925.PubMed

105.

Schiemann, B. J., Neil, J. R., & Schiemann, W. P. (2003). SPARC inhibits epithelial cell proliferation in part through stimulation of the TGF-beta-signaling system. Molecular Biology of the Cell, 14(10), 3977–3988.PubMed

106.

Bradshaw, A. D., Reed, M. J., Carbon, J. G., Pinney, E., Brekken, R. A., & Sage, E. H. (2001). Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice. Wound Repair and Regeneration, 9(6), 522–530.PubMed

107.

Peinado, H., Quintanilla, M., & Cano, A. (2003). Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: Mechanisms for epithelial mesenchymal transitions. Journal of Biological Chemistry, 278(23), 21113–21123.PubMed

108.

McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J., Brunton, V. G., & Frame, M. C. (2005). The role of focal-adhesion kinase in cancer—A new therapeutic opportunity. Nature Reviews. Cancer, 5(7), 505–515.PubMed

109.

Shi, Q., Bao, S., Song, L., Wu, Q., Bigner, D. D., Hjelmeland, A. B., et al. (2007). Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene, 26(28), 4084–4094.PubMed

110.

Coussens, L. M., & Werb, Z. (1996). Matrix metalloproteinases and the development of cancer. Chemistry & Biology, 3, 895–904.

111.

Alvarez, M. J., Prada, F., Salvatierra, E., Bravo, A. I., Lutzky, V. P., Carbone, C., et al. (2005). Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Research, 65(12), 5123–5132.PubMed

112.

Savani, R. C., Zhou, Z., Arguiri, E., Wang, S., Vu, D., Howe, C. C., et al. (2000). Bleomycin-induced pulmonary injury in mice deficient in SPARC. AJP—Lung Cellular and Molecular Physiology, 279(4), L743–L750.PubMed

113.

Sangaletti, S., Gioiosa, L., Guiducci, C., Rotta, G., Rescigno, M., Stoppacciaro, A., et al. (2005). Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. Journal of Cell Science, 118(Pt 16), 3685–3694.PubMed

114.

Rempel, S. A., Hawley, R. C., Gutierrez, J. A., Mouzon, E., Bobbitt, K. R., Lemke, N., et al. (2007). Splenic and immune alterations of the Sparc-null mouse accompany a lack of immune response. Genes and Immunity, 8(3), 262–274.PubMed

115.

Vannahme, C., Gosling, S., Paulsson, M., Maurer, P., & Hartmann, U. (2003). Characterization of SMOC-2, a modular extracellular calcium-binding protein. Biochemical Journal, 373(Pt 3), 805–814.PubMed

116.

Rocnik, E. F., Liu, P., Sato, K., Walsh, K., & Vaziri, C. (2006). The novel SPARC family member SMOC-2 potentiates angiogenic growth factor activity. Journal of Biological Chemistry, 281(32), 22855–22864.PubMed

117.

Girard, J.-P., & Springer, T. A. (1995). Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity, 2, 113–123.PubMed

118.

Girard, J.-P., & Springer, T. A. (1996). Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. Journal of Biological Chemistry, 271(8), 4511–4517.PubMed

119.

Nelson, P. S., Plymate, S. R., Wang, K., True, L. D., Ware, J. L., Gan, L., et al. (1998). Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Research, 58(2), 232–236.PubMed

120.

Bendik, I., Schraml, P., & Ludwig, C. U. (1998). Characterization of MAST9/Hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Research, 58(4), 626–629.PubMed

121.

Claeskens, A., Ongenae, N., Neefs, J. M., Cheyns, P., Kaijen, P., Cools, M., et al. (2000). Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. British Journal of Cancer, 82(6), 1123–1130.PubMed

122.

Esposito, I., Kayed, H., Keleg, S., Giese, T., Sage, E. H., Schirmacher, P., et al. (2007). Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia, 9(1), 8–17.PubMed

123.

Jazaeri, A. A., Awtrey, C. S., Chandramouli, G. V., Chuang, Y. E., Khan, J., Sotiriou, C., et al. (2005). Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clinical Cancer Research, 11(17), 6300–6310.PubMed

124.

Briggs, J., Chamboredon, S., Castellazzi, M., Kerry, J. A., & Bos, T. J. (2002). Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene, 21(46), 7077–7091.PubMed

125.

Lopez, M. V., Blanco, P., Viale, D. L., Cafferata, E. G., Carbone, C., Gould, D., et al. (2006). Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth. Molecular Cancer Therapeutics, 5(10), 2503–2511.PubMed

126.

Zajchowski, D. A., Bartholdi, M. F., Gong, Y., Webster, L., Liu, H.-L., Munishkin, A., et al. (2001). Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Research, 61(13), 5168–5178.PubMed

127.

Woelfle, U., Cloos, J., Sauter, G., Riethdorf, L., Janicke, F., van Diest, P., et al. (2003). Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Research, 63(18), 5679–5684.PubMed

128.

Watkins, G., Martin, T. A., Bryce, R., Mansel, R. E., & Jiang, W. G. (2005). Gamma-Linolenic acid regulates the expression and secretion of SPARC in human cancer cells. Prostaglandins, Leukotrienes and Essential Fatty Acids, 72(4), 273–278.

129.

Castronovo, V., & Bellahcene, A. (1998). Evidence that breast cancer associated microcalcifications are mineralized malignant cells. International Journal of Oncology, 12(2), 305–308.PubMed

130.

Porter, D., Lahti-Domenici, J., Keshaviah, A., Bae, Y. K., Argani, P., Marks, J., et al. (2003). Molecular markers in ductal carcinoma in situ of the breast. Molecular Cancer Research, 1(5), 362–375.PubMed

131.

Dairkee, S. H., Ji, Y., Ben, Y., Moore, D. H., Meng, Z., & Jeffrey, S. S. (2004). A molecular ‘signature’ of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics, 5, 47.PubMed

132.

Amatschek, S., Koenig, U., Auer, H., Steinlein, P., Pacher, M., Gruenfelder, A., et al. (2004). Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Research, 64(3), 844–856.PubMed

133.

Jansen, M. P. H. M., Foekens, J. A., van Staveren, I. L., Dirkzwager-Kiel, M. M., Ritstier, K., Look, M. P., et al. (2005). Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. Journal of Clinical Oncology, 23(4), 732–740.PubMed

134.

Sturm, R. A., Satyamoorthy, K., Meier, F., Gardiner, B. B., Smit, D. J., Vaidya, B., et al. (2002). Osteonectin/SPARC induction by ectopic b₃ integrin in human radial growth phase primary melanoma cells. Cancer Research, 62, 226–232.PubMed

135.

Kuphal, S., Palm, H. G., Poser, I., & Bosserhoff, A. K. (2005). Snail-regulated genes in malignant melanoma. Melanoma Research, 15(4), 305–313.PubMed

136.

Menon, P. M., Gutierrez, J. A., & Rempel, S. A. (2000). A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: High SPARC secretion correlates with decreased migration on vitronectin. International Journal of Oncology, 17(4), 683–693.PubMed

137.

Huang, H., Colella, S., Kurrer, M., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2000). Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Research, 60(24), 6868–6874.PubMed

138.

Rempel, S. A., Golembieski, W. A., Fisher, J. L., Maile, M., & Nakeff, A. (2001). SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. Journal of Neuro-oncology, 53, 149–160.PubMed

139.

Golembieski, W. A., & Rempel, S. A. (2002). cDNA array analysis of SPARC-modulated changes in glioma gene expression. Journal of Neuro-oncology, 60(3), 213–226.PubMed

140.

Zhou, X., Tan, F. K., Guo, X., Wallis, D., Milewicz, D. M., Xue, S., et al. (2005). Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts. Arthritis and Rheumatism, 52(1), 257–261.PubMed

141.

Cantarella, G., Risuglia, N., Dell’eva, R., Lempereur, L., Albini, A., Pennisi, G., et al. (2006). TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. British Journal of Cancer, 94(10), 1428–1435.PubMed

142.

Kunigal, S., Gondi, C. S., Gujrati, M., Lakka, S. S., Dinh, D. H., Olivero, W. C., et al. (2006). SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. International Journal of Oncology, 29(6), 1349–1357.PubMed

143.

Gagliano, N., Moscheni, C., Torri, C., Magnani, I., Bertelli, A. A., Nowicky, W., et al. (2006). Effect of Ukrain on matrix metalloproteinase-2 and secreted protein acidic and rich in cysteine (SPARC) expression in human glioblastoma cells. Anticancer Drugs, 17(2), 189–194.PubMed

144.

Colin, C., Baeza, N., Bartoli, C., Fina, F., Eudes, N., Nanni, I., et al. (2006). Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using suppression subtractive hybridization. Oncogene, 25(19), 2818–2826.PubMed

145.

Rempel, S. A., Ge, S., & Gutiérrez, J. A. (1999). SPARC: A potential diagnostic marker of invasive meningiomas. Clinical Cancer Research, 5, 237–241.PubMed

146.

Rich, J. N., Hans, C., Jones, B., Iversen, E. S., McLendon, R. E., Rasheed, B. K., et al. (2005). Gene expression profiling and genetic markers in glioblastoma survival. Cancer Research, 65(10), 4051–4058.PubMed

147.

Volmer, M. W., Radacz, Y., Hahn, S. A., Klein-Scory, S., Stuhler, K., Zapatka, M., et al. (2004). Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a “secretome” analysis. Proteomics, 4(5), 1324–1334.PubMed

148.

Sansom, O. J., Mansergh, F. C., Evans, M. J., Wilkins, J. A., & Clarke, A. R. (2007). Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice. Gut, 56(10), 1410–1414.PubMed

149.

Madoz-Gurpide, J., Lopez-Serra, P., Martinez-Torrecuadrada, J. L., Sanchez, L., Lombardia, L., & Casal, J. I. (2006). Proteomics-based validation of genomic data: Applications in colorectal cancer diagnosis. Molecular & Cellular Proteomics, 5(8), 1471–1483.

150.

Kaiser, S., Park, Y. K., Franklin, J. L., Halberg, R. B., Yu, M., Jessen, W. J., et al. (2007). Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biology, 8, R131.PubMed

151.

Lecrone, V., Li, W., Devoll, R. E., Logothetis, C., & Farach-Carson, M. C. (2000). Calcium signals in prostate cancer cells: Specific activation by bone-matrix proteins. Cell Calcium, 27(1), 35–42.PubMed

152.

Thomas, R., True, L. D., Bassuk, J. A., Lange, P. H., & Vessella, R. L. (2000). Differential expression of osteonectin/SPARC during human prostate cancer progression. Clinical Cancer Research, 6(3), 1140–1149.PubMed

153.

Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 101(3), 811–816.PubMed

154.

Best, C. J., Gillespie, J. W., Yi, Y., Chandramouli, G. V., Perlmutter, M. A., Gathright, Y., et al. (2005). Molecular alterations in primary prostate cancer after androgen ablation therapy. Clinical Cancer Research, 11(19 Pt 1), 6823–6834.PubMed

155.

Kato, Y., Sakai, N., Baba, M., Kaneko, S., Kondo, K., Kubota, Y., et al. (1998). Stimulation of motility of human renal cell carcinoma by SPARC/Osteonectin/BM-40 associated with type IV collagen. Invasion Metastasis, 18(2), 105–114.PubMed

156.

Sakai, N., Baba, M., Nagasima, Y., Kato, Y., Hirai, K., Kondo, K., et al. (2001). SPARC expression in primary human renal cell carcinoma: Upregulation of SPARC in sarcomatoid renal carcinoma. Human Pathology, 32(10), 1064–1070.PubMed

157.

Gieseg, M. A., Cody, T., Man, M. Z., Madore, S. J., Rubin, M. A., & Kaldjian, E. P. (2002). Expression profiling of human renal carcinomas with functional taxonomic analysis. BMC Bioinformatics, 3, 26.PubMed

158.

Luo, A., Kong, J., Hu, G., Liew, C. C., Xiong, M., Wang, X., et al. (2004). Discovery of Ca2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene, 23(6), 1291–1299.PubMed

159.

Mitas, M., Almeida, J. S., Mikhitarian, K., Gillanders, W. E., Lewin, D. N., Spyropoulos, D. D., et al. (2005). Accurate discrimination of Barrett’s esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clinical Cancer Research, 11(6), 2205–2214.PubMed

160.

Che, Y., Luo, A., Wang, H., Qi, J., Guo, J., & Liu, Z. (2006). The differential expression of SPARC in esophageal squamous cell carcinoma. International Journal of Molecular Medicine, 17(6), 1027–1033.PubMed

161.

Porte, H., Triboulet, J. P., Kotelevets, L., Carrat, F., Prevot, S., Nordlinger, B., et al. (1998). Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: Implications for prognosis. Clinical Cancer Research, 4(6), 1375–1382.PubMed

162.

Yamashita, K., Upadhay, S., Mimori, K., Inoue, H., & Mori, M. (2003). Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer, 97(10), 2412–2419.PubMed

163.

Brabender, J., Marjoram, P., Lord, R. V., Metzger, R., Salonga, D., Vallbohmer, D., et al. (2005). The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett’s esophagus and patients with Barrett’s-associated adenocarcinoma. Cancer Epidemiology, Biomarkers & Prevention, 14(9), 2113–2117.

164.

Siddiq, F., Sarkar, F. H., Wali, A., Pass, H. I., & Lonardo, F. (2004). Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung. Lung Cancer, 45(2), 197–205.PubMed

165.

De Vos, J., Thykjaer, T., Tarte, K., Ensslen, M., Raynaud, P., Requirand, G., et al. (2002). Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene, 21(44), 6848–6857.PubMed

166.

Hedvat, C. V., Comenzo, R. L., Teruya-Feldstein, J., Olshen, A. B., Ely, S. A., Osman, K., et al. (2003). Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. British Journal of Haematology, 122(5), 728–744.PubMed

167.

Martinez, N., Camacho, F. I., Algara, P., Rodriguez, A., Dopazo, A., Ruiz-Ballesteros, E., et al. (2003). The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research, 63(23), 8226–8232.PubMed

168.

Aouacheria, A., Navratil, V., Lopez-Perez, R., Gutierrez, N. C., Churkin, A., Barash, D., et al. (2007). In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions. BMC Genomics, 8, 2.PubMed

169.

Bloomston, M., Ellison, E. C., Muscarella, P., Al-Saif, O., Martin, E. W., Melvin, W. S., et al. (2007). Stromal osteonectin overexpression is associated with poor outcome in patients with ampullary cancer. Annals of Surgical Oncology, 14(1), 211–217.PubMed

170.

Prenzel, K. L., Warnecke-Eberz, U., Xi, H., Brabender, J., Baldus, S. E., Bollschweiler, E., et al. (2006). Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. Oncology Reports, 15(5), 1397–1401.PubMed

171.

Le Bail, B., Faouzi, S., Boussarie, L., Guirouilh, J., Blanc, J. F., Carles, J., et al. (1999). Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. Journal of Pathology, 189(1), 46–52.PubMed

172.

Goldenberg, D., Ayesh, S., Schneider, T., Pappo, O., Jurim, O., Eid, A., et al. (2002). Analysis of differentially expressed genes in hepatocellular carcinoma using cDNA arrays. Molecular Carcinogenesis, 33, 113–124.PubMed

173.

Maeng, H. Y., Song, S. B., Choi, D. K., Kim, K. E., Jeong, H. Y., Sakaki, Y., et al. (2002). Osteonectin-expressing cells in human stomach cancer and their possible clinical significance. Cancer Letters, 184(1), 117–121.PubMed

174.

Inoue, H., Matsuyama, A., Mimori, K., Ueo, H., & Mori, M. (2002). Prognostic score of gastric cancer determined by cDNA microarray. Clinical Cancer Research, 8(11), 3475–3479.PubMed

175.

Wang, C. S., Lin, K. H., Chen, S. L., Chan, Y. F., & Hsueh, S. (2004). Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance. British Journal of Cancer, 91(11), 1924–1930.PubMed

176.

Paley, P. J., Goff, B. A., Gown, A. M., Greer, B. E., & Sage, E. H. (2000). Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecologic Oncology, 78(3 Pt 1), 336–341.PubMed

177.

Nimphius, W., Moll, R., Olbert, P., Ramaswamy, A., & Barth, P. J. (2007). CD34+ fibrocytes in chronic cystitis and noninvasive and invasive urothelial carcinomas of the urinary bladder. Virchows Archiv, 450(2), 179–185.PubMed

178.

Yamanaka, M., Kanda, K., Li, N.-C., Fukumori, T., Oka, N., Kanayama, H.-O., et al. (2001). Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. Journal of Urology, 166, 2495–2499.PubMed

179.

Chen, Y., Miller, C., Mosher, R., Zhao, X., Deeds, J., Morrissey, M., et al. (2003). Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Research, 63(8), 1927–1935.PubMed

180.

Sova, P., Feng, Q., Geiss, G., Wood, T., Strauss, R., Rudolf, V., et al. (2006). Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiology, Biomarkers & Prevention, 15(1), 114–123.

181.

Rodriguez-Jimenez, F. J., Caldes, T., Iniesta, P., Vidart, J. A., Garcia-Asenjo, J. L., & Benito, M. (2007). Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma. Oncology Reports, 17(6), 1301–1307.PubMed

182.

Fanburg-Smith, J. C., Bratthauer, G. L., & Miettinen, M. (1999). Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcoma: A study of 28 cases. Human Pathology, 30(1), 32–38.PubMed

183.

Dalla-Torre, C. A., Yoshimoto, M., Lee, C. H., Joshua, A. M., de Toledo, S. R., Petrilli, A. S., et al. (2006). Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer, 6(1), 237.PubMed

184.

Takano, T., Hasegawa, Y., Miyauchi, A., Matsuzuka, F., Yoshida, H., Kuma, K., et al. (2002). Quantitative analysis of osteonectin mRNA in thyroid carcinomas. Endocrine Journal, 49(4), 511–516.PubMed

185.

Chin, D., Boyle, G. M., Williams, R. M., Ferguson, K., Pandeya, N., Pedley, J., et al. (2005). Novel markers for poor prognosis in head and neck cancer. International Journal of Cancer, 113(5), 789–797.

186.

Aycock, R. L., Bradshaw, A. C., Sage, E. H., & Starcher, B. (2004). Development of UV-induced squamous cell carcinomas is suppressed in the absence of SPARC. Journal of Investigative Dermatology, 123(3), 592–599.PubMed

187.

Said, N., Najwer, I., & Motamed, K. (2007). Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. American Journal of Pathology, 170(3), 1054–1063.PubMed

188.

Cody, N. A., Ouellet, V., Manderson, E. N., Quinn, M. C., Filali-Mouhim, A., Tellis, P., et al. (2007). Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene, 26(4), 618–632.PubMed

189.

Dhanesuan, N., Sharp, J. A., Blick, T., Price, J. T., & Thompson, E. W. (2002). Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Research and Treatment, 75(1), 73–85.PubMed

190.

Bergamaschi, A., Tagliabue, E., Sorlie, T., Naume, B., Triulzi, T., Orlandi, R., et al. (2007). Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. Journal of Pathology, 214(3), 357–367.

191.

Tang, H., Wang, J., Bai, F., Hong, L., Liang, J., Gao, J., et al. (2007). Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochemistry and Cell Biology, 85(1), 103–110.PubMed

192.

Chlenski, A., Liu, S., Guerrero, L. J., Yang, Q., Tian, Y., Salwen, H. R., et al. (2006). SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. International Journal of Cancer, 118(2), 310–316.

193.

Chlenski, A., Guerrero, L. J., Yang, Q., Tian, Y., Peddinti, R., Salwen, H. R., et al. (2007). SPARC enhances tumor stroma formation and prevents fibroblast activation. Oncogene, 26(31), 4513–4522.PubMed

194.

Puolakkainen, P., Bradshaw, A. D., Kyriakides, T. R., Reed, M., Brekken, R., Wight, T., et al. (2003). Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. American Journal of Pathology, 162(2), 627–635.PubMed

195.

DiMartino, J. F., Lacayo, N. J., Varadi, M., Li, L., Saraiya, C., Ravindranath, Y., et al. (2006). Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia, 20(3), 426–432.PubMed

Springer Medizin

The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2008

Imaging of integrin αvβ3 expression

Biography - Anthony F. Shields, M.D., Ph.D.

Imaging of tumor glucose utilization with positron emission tomography

Preface-imaging in cancer